- Lexaria Bioscience (CSE:LXX) has filed a new US patent application for the use of its DehydraTECH technology in the delivery of antiviral drugs
- Lexaria believes the technology could be used to improve treatments for diseases like COVID-19, MERS, SARS, influenza and AIDS
- The technology has already been used in the oral delivery of lipophilic drugs, such as nicotine and cannabinoids
- The company plans to file for additional patent protection in other international markets
- Lexaria Bioscience (LXX) is currently down 2.27 per cent to C$0.43 per share, with a market cap of $33.99 million
Lexaria Bioscience (CSE:LXX) has filed a new US patent application for the use of its DehydraTECH technology in the delivery of antiviral drugs.
The British Columbia-based company operates a federally licensed in-house research laboratory, and currently holds 16 granted patents with a further 60 pending worldwide.
Its proprietary DehydraTECH technology changes the way that active pharmaceutical ingredients enter the bloodstream. The effects of the technology help to increase bio-absorption, reduce the time of onset and reduce costs for orally administered bioactive molecules.
In light of the current COVID-19 crisis, Lexaria is focussing its efforts on DehydraTECH’s ability to improve treatment options for viral infectious diseases. These include the novel coronavirus, MERS, SARS, influenza, herpes, hepatitis and AIDS.
The company’s patent application includes both method-of-use and composition-of-matter claims. It also describes the use of DehydraTECH to develop dosage forms suitable for mucosal tissue, nasal, and other methods of application less common than traditional injecting.
John Docherty, President of Lexaria Bioscience, noted that DehydraTECH has already proven its effectiveness in the oral delivery of lipophilic drugs, such as nicotine, cannabinoids and more.
“We hypothesize that, once detailed testing begins, DehydraTECH will evidence improvements in the quantity and rapidity with which certain antiviral drugs are able to reach the human bloodstream after oral delivery.
“This has the potential to make a real contribution in the fight against COVID-19,” he said.
In addition to filing for a US patent, Lexaria said that it will also pursue patent protection in other international markets.
Lexaria Bioscience (LXX) is currently down 2.27 per cent to C$0.43 per share at 2:14pm EST.